Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Eyebiotech Ltd. (Eyebio)
Headquarters: New York, NY, United States of America
Website: N/A
Year Founded: 2021
Status: Acquired
BioCentury | Nov 23, 2024
Finance
Latest Jeito bet positions European VC for fourth exit
Mega-round for Alentis spotlights French firm’s investment style
BioCentury | Jun 4, 2024
Deals
Deals Report: Two pharmas license neuro assets, and M&A momentum continues
Plus: Galapagos-Adaptimmune enter TCR T cell deal, and digital therapeutics pioneer Akili opts for merger
BioCentury | Jun 4, 2024
Deals
Biotech M&A, Biosecure expands & ASCO update: a BioCentury podcast
An M&A quartet. House China committee’s new focus. Colorectal cancer immunotherapies.
BioCentury | May 29, 2024
Deals
Clinical readout spurred Merck’s $1.3B takeout of VC-backed ophthalmic play EyeBio
In milestone-heavy deal worth up to $3B total, the pharma makes a big commitment to late-stage candidate for retinal diseases
BioCentury | Nov 15, 2023
Finance
Nov. 14 Quick Takes: TPG leads $85M B round for ADC play MBrace
Plus: Nouscom raises €67.5M series C and more from Eyebio, Glox, Bayer and Ketabon
BioCentury | Oct 25, 2023
Emerging Company Profile
Aiolos: going for best in class with a long-acting TSLP mAb for asthma
Start-up, which launched with a $245M series A, is taking on AstraZeneca-Amgen drug with a mAb in-licensed from China-based Hengrui
BioCentury | Jul 13, 2023
Emerging Company Profile
Tenpoint: a toolbox of ex vivo and in vivo treatments for vision loss
F-Prime, Sofinnova, British Patient Capital invest $70M in company with ex vivo stem cell and in vivo cell reprogramming platforms
BioCentury | Mar 7, 2023
Product Development
Eyebiotech targets Wnt pathway with first retinal program
Biotech discloses details one year after $65M series A round
BioCentury | Feb 23, 2022
Finance
Jeito joins NMD’s syndicate to help Danish play build clinical, U.S. strategy
The French VC attracted by NMD’s ability to identify patients with severe neuromuscular disease likely to respond to therapy
BioCentury | Feb 23, 2022
Emerging Company Profile
Eyebiotech launches with $65M for experienced ophthalmology team
Eyebiotech targets multispecific, long-acting assets for eye diseases
Items per page:
1 - 10 of 10